MARKHAM, ON, March 2 /PRNewswire-FirstCall/ - Nuvo Research Inc. today announced the publication of a research paper in the March 1st, 2006 issue of the Journal of Rheumatology entitled “Pennsaid(R) Therapy for Osteoarthritis of the Knee: A Systemic Review and Metaanalysis of Randomized Controlled Trials”. The author, Dr. Tanveer E. Towheed, MD, Associate Professor of Medicine and of Community Health and Epidemiology in the Department of Medicine at Queen’s University, concluded that Pennsaid(R) is an effective topical non-steroidal anti-inflammatory (NSAID) in patients with osteoarthritis of the knee and that, apart from minor localized skin reactions, Pennsaid(R) was as safe as the vehicle control placebo.
“We are pleased to see the publication of this independent review, in which the author notes the high quality of our clinical trials and reaffirms the efficacy and safety of Pennsaid in the treatment of osteoarthritis,” said Dr. Henrich Guntermann, Nuvo’s President and CEO.
The objective of the paper was to systematically review four randomized controlled trials evaluating Pennsaid(R) treatment of patients with osteoarthritis of the knee. As reported in the paper, Pennsaid(R) treatment resulted in a significant difference in favour of Pennsaid(R) for pain, stiffness, and physical function and patient global assessment measured by the Western Ontario and McMaster Osteoarthritis Index (WOMAC), when compared to vehicle control placebo. Pennsaid(R) was as safe as vehicle control placebo, with the only exception that it was more likely to result in minor skin dryness at the site of application. In a head-to-head equivalence trial using the WOMAC subscales over 12 weeks, Pennsaid(R) was as effective as oral diclofenac, but was much better tolerated.
Pennsaid(R) is a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries.
About Nuvo Research Inc.
Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the Company’s skin-penetrating technologies. Nuvo’s lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety of indications.
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany. For more information, please visit www.nuvoresearch.com.
This release may contain forward-looking statements, subject to risks and uncertainties beyond management’s control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company’s annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.
Nuvo Research Inc.
CONTACT: Investor Relations: Christina Bessant, Equicom Group Inc., (416)815-0700 x269, cbessant@equicomgroup.com; Archived images on thisorganization are searchable through CNW Photo Archive website athttp://photos.newswire.ca. Images are free to accredited members of themedia. To request a free copy of this organization’s annual report, pleasego to http://www.newswire.ca and click on Tools for Investors.
